Benzinga · Sep 23, 2026
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
ED
NASDAQ · EDIT
Editas Medicine, Inc.
Healthcare · Biotechnology
$2.79
Down-$0.06 (-2.15%)
Updated Oct 6, 2026, 9:41 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 217.72M
- P/E ratio
- -0.91
- Dividend yield
- 0.00%
- 52-week range
- $1.98 – $3.94
- Volume
- 3.02M
- Avg. volume
- 2.47M
Price performance · EDIT
EDIT price history
1M range · 0 trading sessions · Daily adjusted prices
EDIT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest EDIT news
The latest Smart Investors Daily articles mentioning EDIT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EDIT research
Overview
Company profile and research snapshot.
Company profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.85
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Guggenheim | Buy | — |
| Aug 18, 2026 | Ladenburg Thalmann | Buy | — |
| May 5, 2026 | Chardan Capital | Buy | — |
| Mar 10, 2026 | Jones Trading | Buy | — |
| Mar 9, 2026 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 12, 2026
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol. Speaking at the Cantor Healthcare Conference, President and Chief Executive
Yahoo · Sep 9, 2026
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory, M.D. In connection with Dr. Ory’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Ory as an inducement material to Dr. Ory entering into employment with Editas
Yahoo · Sep 9, 2026
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion. O’Ne
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
